We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+34.16%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$913M
AUM Growth
+$115M
Cap. Flow
-$67.2M
Cap. Flow %
-7.37%
Top 10 Hldgs %
28.56%
Holding
108
New
15
Increased
30
Reduced
36
Closed
14

Top Buys

Rank Stock Value
1
GH icon
Guardant Health
GH
+$8.67M
2
AXNX
Axonics, Inc. Common Stock
AXNX
+$7.88M
3
ISRG icon
Intuitive Surgical
ISRG
+$6.74M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$6.19M
5
LIVN icon
LivaNova
LIVN
+$6.07M

Top Sells

Rank Stock Value
1
CVS icon
CVS Health
CVS
+$11.5M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$11.3M
3
TMO icon
Thermo Fisher Scientific
TMO
+$11.1M
4
COR icon
Cencora
COR
+$8.15M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$7.67M

Sector Composition

Rank Sector Weight
1 Healthcare 93.54%
2 Financials 0.09%
3 Energy 0.09%
4 Technology 0.09%
5 Communication Services 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRAY
76
DELISTED
ViewRay, Inc.
VRAY
$3.17M 0.35%
750,000
+114,566
+18% +$370K
RGNX icon
77
Regenxbio
RGNX
$708M
$3.07M 0.34%
+75,000
New +$2.96M
CLLS
78
Cellectis
CLLS
$285M
$2.48M 0.27%
+144,604
New +$1.93M
APLS
79
DELISTED
Apellis Pharmaceuticals
APLS
$2.45M 0.27%
+80,000
New +$2.21M
VKTX icon
80
Viking Therapeutics
VKTX
$4B
$1.6M 0.18%
200,000
– –
PVLA
81
Palvella Therapeutics
PVLA
$2.27B
$1.09M 0.12%
3,750
– –
CVX icon
82
Chevron
CVX
$366B
$358K 0.04%
2,974
– –
DIS icon
83
Walt Disney
DIS
$181B
$301K 0.03%
2,083
– –
QCOM icon
84
Qualcomm
QCOM
$176B
$299K 0.03%
3,391
– –
IBM icon
85
IBM
IBM
$224B
$297K 0.03%
2,317
– –
JPM icon
86
JPMorgan Chase
JPM
$950B
$292K 0.03%
2,095
-377
-15% -$48.4K
WFC icon
87
Wells Fargo
WFC
$264B
$284K 0.03%
5,272
– –
F icon
88
Ford
F
$55.7B
$271K 0.03%
29,164
– –
XOM icon
89
ExxonMobil
XOM
$634B
$269K 0.03%
3,854
– –
JHG
90
DELISTED
Janus Henderson
JHG
$260K 0.03%
10,645
– –
BUD icon
91
AB InBev
BUD
$165B
$230K 0.03%
2,806
-603
-18% -$50.2K
GEN icon
92
Gen Digital
GEN
$17.5B
$224K 0.02%
8,761
– –
GOOGL icon
93
Alphabet (Google) Class A
GOOGL
$4.33T
$214K 0.02%
+3,200
New +$206K
HAL icon
94
Halliburton
HAL
$26.6B
$203K 0.02%
+8,299
New +$175K
CHRS icon
95
Coherus Oncology
CHRS
$196M
– –
-290,000
Closed -$5.88M
COR icon
96
Cencora
COR
$61.2B
– –
-99,000
Closed -$8.15M
EXEL icon
97
Exelixis
EXEL
$13.4B
– –
-320,000
Closed -$5.66M
MDGL icon
98
Madrigal Pharmaceuticals
MDGL
$11.8B
– –
-30,000
Closed -$2.59M
MSFT icon
99
Microsoft
MSFT
$3.71T
– –
-1,532
Closed -$213K
TMO icon
100
Thermo Fisher Scientific
TMO
$220B
– –
-38,000
Closed -$11.1M
1 2 3
4
5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2019 Portfolio in Review

As of Q4 2019, Rhenman & Partners Asset Management held 108 positions worth $913M, up 14% from $798M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $67.2M in Q4 2019, closing 14 positions and reducing 36 holdings. Its most notable exit was Thermo Fisher Scientific, an estimated $11.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Financials and Energy.

Against the trend, Rhenman & Partners Asset Management opened a new position in Axonics, Inc. Common Stock worth $9.14M.

  • Rhenman & Partners Asset Management's largest Q4 2019 buy was Axonics, Inc. Common Stock: 330,000 shares worth $9.14M.
  • Rhenman & Partners Asset Management added most to Guardant Health in Q4 2019, an estimated $8.67M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2019 reduction was CVS Health, cutting an estimated $11.5M.
  • Rhenman & Partners Asset Management fully exited Thermo Fisher Scientific in Q4 2019, selling an estimated $11.1M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $913M portfolio in Q4 2019.
  • Rhenman & Partners Asset Management opened 15 new positions and closed 14 in Q4 2019.
  • Rhenman & Partners Asset Management's portfolio value rose 14% quarter-over-quarter to $913M.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2019, filed 17 Jan 2020.